Abstract:Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer (NK) cells are emerging tools for cancer therapy. However, only subpopulations of NK cells that are differentially controlled by inhibitory receptors exert reactivity against particular cancer types. How to leverage the complete anti-tumor potential of all NK cell subsets without favoring the emergence of NK cell-resistant tumor cells remains unresolved. Methods We performed a genome-wide CRISPR/Cas9 knockout resistance screen in melanoma cells in co-cultures with human primary NK cells. We comprehensively evaluated factors regulating tumor resistance and susceptibility by focusing on NK cell subsets in an allogenic setting. Moreover, we tested therapeutic blocking antibodies currently used in clinical trials. Results Melanoma cells deficient in antigen-presenting or the IFNγ-signaling pathways were depleted in remaining NK cell-co-cultured melanoma cells and displayed enhanced sensitivity to NK cells. Treatment with IFNγ induced potent resistance of melanoma cells to resting, IL-2-cultured and ADCC-activated NK cells that depended on B2M required for the expression of both classical and non-classical MHC-I. IFNγ-induced expression of HLA-E mediated the resistance of melanoma cells to the NKG2A + KIR − and partially to the NKG2A + KIR + NK cell subset. The expression of classical MHC-I by itself was sufficient for the inhibition of the NKG2A − KIR + , but not the NKG2A + KIR + NK cell subset. Treatment of NK cells with monalizumab, an NKG2A blocking mAb, enhanced the reactivity of a corresponding subset of NK cells. The combination of monalizumab with lirilumab, blocking KIR2 receptors, together with DX9, blocking KIR3DL1, was required to restore cytotoxicity of all NK cell subsets against IFNγ-induced resistant tumor cells in melanoma and tumors of different origins. Conclusion Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.

NK cells promote cancer immunoediting through tumor-intrinsic loss of interferon-stimulated gene expression

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

Tumor-Induced Suppression of Interferon-Gamma Production and Enhancement of Interleukin-10 Production by Natural Killer (nk) Cells: Paralleled to Cd4(+) T Cells

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion

Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing

FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity

TGF-β and CIS inhibition overcomes NK cell suppression to restore anti-tumor immunity

Tumour cells can escape antiproliferative pressure by interferon-β through immunoediting of interferon receptor expression

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Tumor-associated NK cells facilitate tumor growth via NKp46 in immunocompetent murine hepatocellular carcinoma

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation

IFN-γ Mediates CD4+ T-cell Loss and Impairs Secondary Antitumor Responses after Successful Initial Immunotherapy

Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

Natural killer cells in cancer biology and therapy

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?